Consistent with previous studies, VTE that occurred in the peri-diagnostic period (one month prior to and after cancer diagnosis) accounted for 32%~45% (10, 23) and 23%~35% (9, 38, 40) of all VTEs in the ROS1 or ALK positive cohort, respectively. The gene discussed is ALK; the disease is cancer.